Skip to Main Content

Kura Oncology presented early clinical trial results Saturday showing for the first time that its genetically targeted cancer drug can induce responses — including complete remission — in patients with advanced leukemia.

The data are preliminary, but suggest that the Kura drug, a once-daily pill called KO-539, could become an effective treatment for certain types of genetically defined acute myeloid leukemia (AML), a rapidly progressing bone marrow cancer that affects adults. The drug could also be used eventually to treat children with a different form of leukemia.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!